Janice Wahl

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

David Roth, David R. Nelson, Annette Bruchfeld et al. · The Lancet · 2015 · 666 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

Stefan Zeuzem, Reem Ghalib, K. Rajender Reddy et al. · Annals of Internal Medicine · 2015 · 517 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

Gregory J. Dore, Frederick L. Altice, Alain H. Litwin et al. · Annals of Internal Medicine · 2016 · 363 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

Jürgen K. Rockstroh, Mark Nelson, Christine Katlama et al. · The Lancet HIV · 2015 · 306 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Eric Lawitz, Edward Gane, Brian L. Pearlman et al. · The Lancet · 2014 · 300 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16